Find information on thousands of medical conditions and prescription drugs.

Chronic myelogenous leukemia

Chronic myelogenous leukemia (or CML) is a form of chronic leukemia characterised by increased production of myeloid cells in the bone marrow. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation termed the Philadelphia chromosome. It is traditionally treated with chemotherapy, interferon and bone marrow transplantation, although a specific inhibitor (imatinib mesylate) has radically changed the management. more...

Home
Diseases
A
B
C
Angioedema
C syndrome
Cacophobia
Café au lait spot
Calcinosis cutis
Calculi
Campylobacter
Canavan leukodystrophy
Cancer
Candidiasis
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Carcinophobia
Cardiac arrest
Cardiofaciocutaneous...
Cardiomyopathy
Cardiophobia
Cardiospasm
Carnitine transporter...
Carnitine-acylcarnitine...
Caroli disease
Carotenemia
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Causalgia
Cayler syndrome
CCHS
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Chalazion
Chancroid
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Chemodectoma
Cherubism
Chickenpox
Chikungunya
Childhood disintegrative...
Chionophobia
Chlamydia
Chlamydia trachomatis
Cholangiocarcinoma
Cholecystitis
Cholelithiasis
Cholera
Cholestasis
Cholesterol pneumonia
Chondrocalcinosis
Chondrodystrophy
Chondromalacia
Chondrosarcoma
Chorea (disease)
Chorea acanthocytosis
Choriocarcinoma
Chorioretinitis
Choroid plexus cyst
Christmas disease
Chromhidrosis
Chromophobia
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cinchonism
Citrullinemia
Cleft lip
Cleft palate
Climacophobia
Clinophobia
Cloacal exstrophy
Clubfoot
Cluster headache
Coccidioidomycosis
Cockayne's syndrome
Coffin-Lowry syndrome
Colitis
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conjunctivitis
Conn's syndrome
Constitutional growth delay
Conversion disorder
Coprophobia
Coproporhyria
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Costochondritis
Cowpox
Craniodiaphyseal dysplasia
Craniofacial dysostosis
Craniostenosis
Craniosynostosis
CREST syndrome
Cretinism
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Croup
Crouzon syndrome
Crouzonodermoskeletal...
Crow-Fukase syndrome
Cryoglobulinemia
Cryophobia
Cryptococcosis
Crystallophobia
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Cystinosis
Cystinuria
Cytomegalovirus
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Signs and symptoms

Patients are often asymptomatic at diagnosis, presenting incidentally with an elevated white blood count on a routine laboratory test. Symptoms may include: malaise, low grade fever, increased susceptibility to infections, anemia and thrombocytopenia with resultant bruising (although an increased platelet count, thrombocytosis, may be a feature). Splenomegaly may also be seen.

The disease may remain dormant for years, but a proportion proceed to accelerated phase (in which the diseases progresses rapidly) or overt blast crisis, which has the symptoms and risks of acute myelogenous leukemia (AML).

Diagnosis

CML is often suspected on the basis on the full blood count, which shows increased granulocytes of all types (including basophils). When the index of suspicion is high, a bone marrow biopsy is required to distinguish CML from other diseases that feature the same symptoms.

Ultimately, CML is diagnosed by detecting the Philadelphia chromosome (a translocation between the 9th and 22nd chromosome leading to an aberrant protein that drives cell division). This translocation leads to bcr-abl fusion and activation of protein tyrosine kinase cascade.

Disease activity can be determined on the basis of the bone marrow examination, cytogenetics and by quantitative PCR.

Pathophysiology

CML was the first malignancy to be linked to a clear genetic abnormality, the chromosomal translocation named Philadelphia chromosome, in 1960. The fusion of two genes on chromosomes 9 and 22, termed abl and bcr respectively, leads to a protein that propels mitosis and causes genomic instability (leading to further mutations).

CML progresses to accelerated phase, and then blast crisis, when additional genetic abnormalities speed up the rate at which new malignant cells are produced in the bone marrow. A second Philadelphia chromosome may appear, as well as deletions of (parts of) chromosomes.

Epidemiology

CML occurs in all age groups, but most commonly in the middle-aged and elderly. Its annual incidence is about 1 per million.

Treatment

Chronic phase

Chronic phase CML is treated with imatinib (marketed as Gleevec or Glivec; previously known as STI-571). In the past, hydroxyurea, alkylating agents (e.g. cytarabine), interferon alfa 2b and steroids were used, but this has been replaced by imatinib. Imatinib is a new agent which specifically targets the abnormality caused by the Philadelphia chromosome. It is better tolerated and more effective than previous therapies. Bone marrow transplants were also used as initial treatment for CML before imatinib and can be curative. In patients who fail to achieve a cytogenetic remission with imatinib or who relapse while on imatinib, a bone marrow transplant should be considered.

Read more at Wikipedia.org


[List your site here Free!]


Bilateral alveolar infiltrates in a 29-year-old man with chronic myelogenous leukemia - pulmonary and critical care pearls
From CHEST, 12/1/02 by Shih-Lung Cheng

A 29-year-old man had received a diagnosis of chronic myelogenous leukemia (CML) 6 years before presentation. He had not undergone bone marrow transplantation because of the lack of an adequate donor. He entered an accelerated phase in 1994 and was treated with oral hydroxyurea and 6-mercaptopurine. The patient developed a dry cough and mild fever in December 2000 and was treated for pneumonia in a local hospital. He was sent to the emergency department of our hospital in April 2001 with a 1-month history of fever, chills, and exertional dyspnea. He also had complained of malaise and a dry cough in the preceding 3 months. There was no history of recent travel, and he was taking no drugs other than hydroxyurea and 6-mercaptopurine.

Physical Examination

The patient's temperature was 38.5[degrees]C, BP was 130/80 mm Hg, pulse was 100 beats/min, and respiration was 40 breaths/min. The sclerae were not icteric. The pupils were isocoric with prompt light reflex. The neck was supple without jugular vein distension or lymphadenopathy. Chest auscultation revealed diffuse, coarse crackles bilaterally. There were no heart murmurs. The abdomen was soft and flat without tenderness or rigidity. The liver and spleen were not palpable. No skin rash or wounds were detected.

Laboratory Findings

The initial laboratory studies revealed the following: WBC count, 26.8 x [10.sup.3] cells/[micro]L with 94% neutrophils; platelet count, 778.0 x [10.sup.3] cells/[micro]L; hemoglobin, 9.0 g/dL; and hematocrit, 28%. The prothrombin time and activated partial thromboplastin time were within normal limits. The aspartate aminotransferase level was 32 U/L, total bilirubin level was 0.9 mg/L, BUN level was 12 mg/L, creatinine level was 0.8 mg/L, and lactate dehydrogenase level was 965 U/L. The urinalysis showed no hematuria or pyuria. Arterial blood gas analysis when breathing 100% oxygen via a nonrebreathing mask showed the following: pH, 7.40; Pa[O.sub.2], 72 mm Hg; PaC[O.sub.2], 28 mm Hg; and HC[O.sub.3.sup.-] level, 18 mEq/L. The induced sputum was negative for Pneumocystis carinii and acid-fast bacilli. Imaging studies, including the chest radiograph taken in the emergency department in April 2001 (Fig 1) and a high-resolution CT (HRCT) scan of the chest taken on the fifth hospital day (Fig 2), are shown.

[FIGURES 1-2 OMITTED]

Hospital Course

An open lung biopsy was performed on the 13th day of the hospital stay. The pathologic findings revealed confluent filling of alveolar spaces with eosinophilic, granular material positive for the periodic acid-Schiff staining which was resistant to diastase. No microorganisms or inflammatory cells could be identified.

What is most likely cause of the bilateral dense pulmonary infiltrates?

What is the most likely diagnosis?

Diagnosis: Secondary alveolar proteinosis complicating CML

Pulmonary alveolar proteinosis is a rare disease characterized by the deposition of a granular extracellular material composed of protein and lipids within the air spaces. Genetic predisposition, smoking, chemical exposure, and dust have been implicated in the pathogenesis of the disease, but the cause remains unknown. It has been hypothesized that alveolar proteinosis may be a consequence of defective macrophage function. The filling of proteinaceous material within the alveoli is thought to impair intra-alveolar anti-infectious mechanisms and, therefore, to be partially responsible for the occurrence of opportunistic infection.

The association of alveolar proteinosis with hematologic disorders, such as leukemia or lymphoma, is well-established, and these forms are considered to be secondary alveolar proteinosis. The incidence of secondary alveolar proteinosis in patients with respiratory symptoms was estimated to be 5.3% among all patients with hematologic malignancies and to be 10% in patients with myeloid disorders. The clinical manifestations of secondary alveolar proteinosis are nonspecific. Dyspnea is most prominent, while nonproductive cough, fatigue, and low-grade fever also may occur. Laboratory investigation may only reveal an elevated serum lactate dehydrogenase level. Typical radiographic findings are bilateral, diffuse, perihilar, ill-defined dense infiltrates, which are usually worse in the lower lung zone. The most common HRCT findings are widespread ground-glass opacity and smooth septal thickening in abnormal areas, and superimposition of these two findings (the so-called "crazy paving" appearance) is characteristic of this disease. A patchy or geographic distribution of consolidation is also a common finding in these patients. The thickened interlobular septa were shown on open lung biopsy to reflect septal inflammation. Septal thickening also can represent interstitial accumulation of material that is positive with periodic acid-Schiff staining. It should be emphasized that septal thickening in patients with alveolar proteinosis is usually visible only in regions of ground-glass opacity.

Pulmonary infections appear to develop with increased frequency in patients with both primary and secondary alveolar proteinosis. Nocardia asteroides and Mycobacterium tuberculosis are the most frequent pathogens reported. Mycobacterium avium-intracellulare (MAI) was isolated from 42% of 19 patients with alveolar proteinosis. Disseminated Mycobacterium abscessus infection without cutaneous manifestations, as in the present case, is extremely rare. To our knowledge, no association of M abscessus infection with alveolar proteinosis has been reported in the literature.

Secondary alveolar proteinosis is potentially reversible without undergoing whole-lung lavage if the underlying disease can be controlled. The prognosis of secondary alveolar proteinosis appears to be related to the prognosis of underlying hematologic malignancy and the curability of any associated infection. Resolution of alveolar proteinosis after successful bone marrow transplantation has been described in three patients with acute myelogenous leukemia and in one patient with acute lymphoid leukemia. Spontaneous recovery from respiratory failure caused by secondary alveolar proteinosis in a patient with leukemia has been reported after neutropenia resolved.

Course and Treatment

IV cefotaxime and erythromycin were administered initially. Trimethoprim-sulfamethoxazole could not be used because of drug allergy. Profound hypoxemia, respiratory distress, and hypotension (ie, BP, 80/40 mm Hg) occurred 2 days later, and the patient was intubated and transferred to the ICUs.

The report of blood culture on the seventh day of hospitalization showed M abscessus. Antibiotics were therefore changed to imipenem, amikacin, and oral clarithromycin. Cultures of bone marrow and BAL fluid also grew the same pathogen.

The whole-lung lavage could not be performed due to severe hypoxemia and difficulties inserting the double-lumen catheter. IV medroxycortisone was administered, but the patient's arterial oxygenation and high ventilatory demand did not improve. Follow-up blood cultures on the 21st and 28th days of the hospital stay did not reveal M abscessus. Cytosine arabinoside at a dose of 20 mg/d was administered from the 35th to the 48th day of the hospital stay as a salvage treatment for CML. The patient's arterial oxygenation and chest radiograph findings gradually improved. He was weaned from mechanical ventilation on the 53rd day of his hospital stay.

CLINICAL PEARLS

1. Alveolar proteinosis should be considered in the differential diagnosis of patients with hematologic malignancies who present with chronic cough, exertional dyspnea, and diffuse alveolar lung infiltrates.

2. Secondary alveolar proteinosis is a possible cause of respiratory failure in patients with hematologic malignancies, especially in myeloid diseases.

3. The most common HRCT findings in patients with alveolar proteinosis are widespread ground-glass opacity and smooth septal thickening in abnormal areas, and the superimposition of these two findings (the so-called crazy paving appearance) is characteristic of this disease.

4. Secondary alveolar proteinosis is potentially reversible without whole-lung lavage, if the underlying disease can be controlled.

5. Pulmonary infections appear to develop with increased frequency in patients with both primary and secondary alveolar proteinosis.

SUGGESTED READINGS

Cordonnier C, Fleury-Feith J, Escudier E, et al. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149:788-794

Gacouin A, Le Tulzo Y, Suprin E, et al. Acute respiratory failure caused by secondary alveolar proteinosis in a patient with acute myeloid leukemia: a case report. Intensive Care Med 1998; 24:265-267

Murch CR, Carr DH. Computed tomography appearances of pulmonary alveolar proteinosis. Clin Radiol 1989; 40:240-243

Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123-1142

Ryan ME, Ferrigo K, O'Boyle T, et al. Periodic fever and skin lesions caused by disseminated Mycobacterium chelonae infection in an immunocompetent child. Pediatr Infect Dis J 1996; 15:270-272

Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73:103-109

* From the Departments of Internal Medicine (Drs. Cheng, Kuo, and Yang) and Laboratory Medicine (Dr. Luh), National Taiwan University Hospital, Taipei, Taiwan.

Manuscript received February 16, 2002; revision accepted March 18, 2002.

Correspondence to: Ping-Hung Kuo, MD, Department of the Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Taipei, Taiwan, Republic of China; e-mail: kph@ha.mc.ntu.edu.tw

COPYRIGHT 2002 American College of Chest Physicians
COPYRIGHT 2003 Gale Group

Return to Chronic myelogenous leukemia
Home Contact Resources Exchange Links ebay